General histone deacetylase (HDAC) inhibitors have been used in blood cancers including AML, but the lack of gene specificity greatly limits their anti-cancer effects and clinical applications. This evidence concerns the gene HDAC9 and hematopoietic and lymphoid system neoplasm.